SillaJen shown out the door, unsettling shareholders from Kosdaq delisting
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The corporate review committee under Korea Exchange on Tuesday decided to delist SillaJen from its bourse, nearly two years since its stock trade have been suspended after former and sitting executives were accused of embezzlement and breach of duty.
A final decision on delisting would be made by the Kosdaq market committee within the next 20 days.
SillaJen plans to appeal, but whether the decision will be overturned is doubtful.
Korea Exchange raised questions about its ongoing value amid stalemate in novel drug pipeline and mere 100 billion won ($83.8 million) fund-raising from M2N.
Shares of Kosdaq-listed M2N, single largest shareholder, have fallen by daily permissible 29.7 percent to 8,150 won in early Wednesday session.
Korea Exchange has been weighing three options – resumption of stock trading, delisting, and delaying decision – for the stock.
SillaJen has endeavored to improve corporate continuity, business transparency, and financial soundness as requested by Korea Exchange to resume stock trade.
Last year, the company issued new shares worth 100 billion won to M2N to bolster capital.
Still, the review committee of Korea Exchange, has not been convinced.
In November 2020, the committee gave the company one year to correct itself.
As of December, the bulk or 92.6 percent of its circulating shares are owned by 174,186 individual investors. A group of SillaJen shareholders released a statement Monday urging the corporate review committee to resume trade as the company has completed improvements.
Minority shareholders of bio stocks on the Kosdaq had been burned from delisting review by authorities.
Kolon TissueGene whose stock has also been suspended since 2019 is also waiting for a decision after Korea Exchange decided to continue its review for another year in December 2020. The bourse operator has demanded Kolon TissueGene to secure funds and resume U.S. clinical trials of its osteoarthritis gene therapy Invossa.
Another stock under delisting review due to similar accusation over embezzlement and breach of duty is Osstem Implant. Korea Exchange plans to decide by January 24 whether the company falls under target for listing eligibility examination.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Seoul delivers $80 mn fine on freight rate collusion in Southeast Asia sea route - Pulse by Maeil Business News Korea
- Korea’s auto output, domestics sales fall, exports value rise in double digits in 2021 - Pulse by Maeil Business News Korea
- Samsung Elec releases mobile processor from 4nm in collabo with AMD - Pulse by Maeil Business News Korea
- Hyundai Motor advised to put off entry to used car market - Pulse by Maeil Business News Korea
- Seoul revises rule to ease budgetary losses over lawsuits with pharma firms - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- HBM 경쟁, SK 1라운드 ‘勝’…삼성 2라운드 ‘선빵’ [맞수맞짱]
- “결혼 전제로 열애”…에일리 연인은 ‘솔로지옥’ 최시훈이었다[공식입장] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이